year 16, Issue 3 (May - June 2022)                   Iran J Med Microbiol 2022, 16(3): 259-266 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sharifi Luyeh M, Ashraf A, Souri Z, Mojtahedi A, Ansar M M. Clinical Features and Predictors associated with Mortality in Non-Survived Patients of COVID-19 in a Referral Hospital in Rasht, North of Iran. Iran J Med Microbiol. 2022; 16 (3) :259-266
1- Department of Anatomy, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
2- Clinical Research Development Unit of Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran
3- Department of Radiology, School of Medicine, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran
4- Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
5- Anatomy Department, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran ,
Abstract:   (452 Views)

Background and Objective: In December 2019, a new type of Coronavirus (SARS-CoV-2) pneumonia (COVID-19) was reported in Wuhan and quickly spread worldwide. This study was designed to investigate the clinical symptoms of the COVID-19 patients.
Methods: In this retrospective study, we collected data of 132 COVID-19 dead patients. Demographic, epidemiological, and clinical data and laboratory test results were analyzed on days 1, 3, and 6 of admission.
Results: Most cases were in the 66-75 age group, 64.39% of which were males. Three days after admission, 55.3% of patients died. The most frequent clinical manifestations were dry cough (70.45%) and fever (54.54%), which increased during hospitalization. Diabetes and blood pressure were reported as the most prevalent underlying diseases. Lymphopenia and an increase in leucocyte number were observed in most patients. ESR (92.5%) and LDH (94.64%) levels were above normal. Furthermore, 42.85% and 44.73% of patients had elevated ALT and AST levels, respectively.
Conclusion: The results of this study revealed that males are more likely to be infected with SARS-CoV-19. Underlying diseases were common among patients and clinical and laboratory symptoms aggravated with a rise in hospitalization time.

Full-Text [PDF 440 kb]   (95 Downloads) |   |   Full-Text (HTML)  (82 Views)  
Type of Study: Original Research Article | Subject: Medical Virology
Received: 2021/11/17 | Accepted: 2022/01/23 | ePublished: 2022/03/20

1. Opriessnig T, Huang YW. Coronavirus disease 2019 (COVID‐19) outbreak: Could pigs be vectors for human infections? Xenotransplantation. 2020;27(2). [DOI:10.1111/xen.12591]
2. Rockett RJ, Arnott A, Lam C, Sadsad R, Timms V, Gray KA, et al. Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling. Nat Med. 2020;26(9):1398-404. [DOI:10.1038/s41591-020-1000-7] [PMID]
3. Bchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020;13(11):1601-10. [DOI:10.1016/j.jiph.2020.07.011] [PMID] [PMCID]
4. Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens. 2020;9(3):231. [DOI:10.3390/pathogens9030231] [PMID] [PMCID]
5. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-8. [DOI:10.1007/s00392-020-01626-9] [PMID] [PMCID]
6. Bohmwald K, Galvez N, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front Cellular Neurosci. 2018;12:386. [DOI:10.3389/fncel.2018.00386] [PMID] [PMCID]
7. Blume C, Jackson CL, Spalluto CM, Legebeke J, Nazlamova L, Conforti F, et al. A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection. Nature Genet. 2021;53(2):205-14. [DOI:10.1038/s41588-020-00759-x] [PMID]
8. Liaskou E, Hirschfield GM, Gershwin ME, editors. Mechanisms of tissue injury in autoimmune liver diseases. Seminars in immunopathology; 2014: Springer. [DOI:10.1007/s00281-014-0439-3] [PMID]
9. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204-18. [DOI:10.18632/oncotarget.23208] [PMID] [PMCID]
10. Li K, Fang Y, Li W, Pan C, Qin P, Zhong Y, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol. 2020;30(8):4407-16. [DOI:10.1007/s00330-020-06817-6] [PMID] [PMCID]
11. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83(3):217-20. [DOI:10.1097/JCMA.0000000000000270] [PMID] [PMCID]
12. Fan L, Fang M, Li Z, Tu W, Wang S, Chen W, et al. Radiomics signature: a biomarker for the preoperative discrimination of lung invasive adenocarcinoma manifesting as a ground-glass nodule. Eur Radiol. 2019;29(2):889-97. [DOI:10.1007/s00330-018-5530-z] [PMID]
13. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-98. [DOI:10.1007/s00134-020-06062-x] [PMID] [PMCID]
14. Hopman J, Allegranzi B, Mehtar S. Managing COVID-19 in Low- and Middle-Income Countries. Jama. 2020;323(16):1549-50. [DOI:10.1001/jama.2020.4169] [PMID]
15. Younes N, Al-Sadeq DW, Al-Jighefee H, Younes S, Al-Jamal O, Daas HI, et al. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. Viruses. 2020;12(6):582. [DOI:10.3390/v12060582] [PMID] [PMCID]
16. Sebastiani P, Nolan VG, Baldwin CT, Abad-Grau MM, Wang L, Adewoye AH, et al. A network model to predict the risk of death in sickle cell disease. Blood. 2007;110(7):2727-35. [DOI:10.1182/blood-2007-04-084921] [PMID] [PMCID]
17. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19-A systematic review. Life Sci. 2020:117788. [DOI:10.1016/j.lfs.2020.117788] [PMID] [PMCID]
18. Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, Quinn TC, et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis. 2013;57 Suppl 3(suppl_3):S139-70. [DOI:10.1093/cid/cit578] [PMID] [PMCID]
19. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9. [DOI:10.1001/jama.2020.1585] [PMID] [PMCID]
20. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. [DOI:10.1016/S0140-6736(20)30211-7]
21. Nikpouraghdam M, Jalali Farahani A, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol. 2020;127:104378. [DOI:10.1016/j.jcv.2020.104378] [PMID] [PMCID]
22. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80(4):401-6. [DOI:10.1016/j.jinf.2020.02.018] [PMID] [PMCID]
23. Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Moller M. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genomics. 2019;13(1):2. [DOI:10.1186/s40246-018-0185-z] [PMID] [PMCID]
24. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity Clin Rev Allergy Immunol, 56 (2019). Clin Rev Allergy Immunol.308-21. [DOI:10.1007/s12016-017-8648-x] [PMID]
25. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. [DOI:10.1056/NEJMoa2002032] [PMID] [PMCID]
26. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5]
27. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-41. [DOI:10.1111/all.14238] [PMID]
28. Mo P, Xing Y, Xiao Y, et al. Clinical Characteristics of Refractory Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2021;73(11):e4208-e4213. [DOI:10.1093/cid/ciaa270] [PMID] [PMCID]
29. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-9. [DOI:10.1136/gutjnl-2020-320926] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc